MET and non-small cell lung carcinoma: In phase II randomized open-label study conducted in previously treated locally advanced or metastatic NSCLC patients (NCT00777309), the combination of tivantinib and erlotinib showed an ORR of 10% vs. 7% of the control arm and a median PFS of 3.8 vs. 2.3 months in the control arm.62 Volitinib (savolitinib) selectively inhibits c-Met activity in an ATP-dependent manner.